Physician profile
Pragna Vanapala
NPI 1386223022
$1,006.92
in general payments reported to CMS, 2019-2025
22 companies · $768 in 2025
The $768 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.63 · 2023: $87.44 · 2024: $128 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $188.40 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $120.59 | 2023-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $98.62 | 2024-2025 | |
| Glaxosmithkline, LLC. | $73.45 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $52.10 | 2025 | Wavewriter Alpha Prime 16 |
| Astellas Pharma US INC | $51.76 | 2025 | Veozah |
| Exact Sciences Corporation | $45.59 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $44.20 | 2024-2025 | Krystexxa, Prolia, Evenity |
| Pfizer INC. | $43.28 | 2025 | |
| Lilly USA, LLC | $36.57 | 2025 | Mounjaro, Zepbound, Kisunla |
| Inspire Medical Systems, INC. | $27.10 | 2025 | Inspire |
| Baxter Healthcare | $26.61 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Dexcom, INC. | $24.62 | 2025 | Dexcom G6 Transmitter |
| Tactile Systems Technology INC | $23.43 | 2025 | Nimbl, Flexitouch Plus |
| Becton, Dickinson and Company | $22.67 | 2025 | Bd Max System, Bd Max Instrument |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $21.86 | 2025 | Keveyis |
| Aerin Medical INC. | $20.66 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $20.57 | 2023 | Nuedexta |
| Abbott Laboratories | $19.59 | 2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $17.20 | 2023 | Quviviq |
| Organon LLC | $14.21 | 2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $13.84 | 2024 | Gardasil 9, Vaxneuvance, Vaxelis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pragna Vanapala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.